The Centers for Medicare & Medicaid Services (CMS) have proposed coverage of home noninvasive ventilation devices for COPD patients.
RT’s Three Key Takeaways:
- CMS Proposal Reflects CHEST Advocacy: CMS has proposed major updates to home noninvasive ventilation (NIV) coverage for COPD patients, incorporating nearly all recommendations from a CHEST expert panel.
- Improved Patient Access: The proposed changes aim to remove long-standing administrative barriers, enabling more timely and appropriate use of NIV devices that improve survival and quality of life for patients with chronic respiratory failure due to COPD.
- CHEST’s Ongoing Leadership: This milestone follows years of CHEST-led collaboration and advocacy, with the organization continuing efforts to ensure final CMS guidelines sustain these patient-centered gains and promote equitable access to care.
The Centers for Medicare & Medicaid Services (CMS) recently released a proposal that includes substantial changes to federal coverage guidelines for NIV devices used in the home, according to The American College of Chest Physicians (CHEST).
The proposal comes after more than a decade of strategic efforts led by CHEST to ensure patients with COPD receive timely access to the most appropriate noninvasive ventilation (NIV) therapies, the organization says.
These proposed guidelines, addressing coverage of noninvasive positive pressure ventilation for patients with chronic respiratory failure due to COPD, reflect nearly all of the major recommendations submitted by a CHEST-convened expert panel.
CMS will cover in the home a RAD (respiratory assist device) with or without backup rate feature immediately upon hospital discharge for an initial 6-month period for patients with acute on chronic respiratory failure due to COPD, if the patient required either a RAD or ventilator within the 24-hour period prior to hospital discharge and the treating clinician determines that the patient is at risk of rapid symptom exacerbation or rise in PaCO2 after discharge.
Patients must be evaluated at least twice within the first year after initially receiving a RAD. Evaluations must occur by the end of the six-month initial coverage period and again during months 7-12.
via CMS.gov
“We are thrilled that CMS has embraced recommendations that will directly enhance patient care in noninvasive ventilation,” said Nicholas Hill, MD, Chair of the CHEST-initiated COPD technical expert panel. “This is the culmination of years of collaborative work by CHEST and the broader respiratory health community, and it is encouraging to see that advocacy leads to real change.”
In 2021, CHEST organized and led technical expert panels to produce comprehensive recommendations for the use of NIV across respiratory conditions, including COPD, OSA, central sleep apnea, thoracic restrictive disorders, and hypoventilation syndromes. The report on COPD supported the submissions to CMS that led to the changes.
The World Health Organization estimates that COPD is the fourth-leading cause of death worldwide, leading to 3.5 million deaths in 2021, and the global community’s eighth-leading cause of poor health. Evidence also suggests that a significant number of people across the globe live with undiagnosed COPD.
NIV is proven to improve quality of life and survival in patients with COPD. Yet outdated or inconsistent coverage policies have historically forced patients and physicians to navigate burdensome barriers, sometimes resulting in inappropriate device use or delayed care. CHEST’s advocacy directly targeted these challenges, calling for policies that streamline access and ensure clinical decisions are driven by patient needs rather than administrative hurdles.
“This is a good sign that progress is being made in the right direction,” said Peter Gay, MD, FCCP, member of the CHEST-initiated COPD technical expert panel. “And we will keep working to share evidence-based arguments until these changes are solidified and can improve the lives of our patients.”
This achievement underscores the substantial, sustained efforts by CHEST members and partners to place patient care at the heart of policy decisions. CHEST continues to advocate to ensure the final guidelines uphold these gains, reduce disparities, and secure equitable, timely access to lifesaving respiratory therapies for all patients with COPD.
